Silo Pharma Secures Canadian Patent for PTSD Treatment, Expanding Global IP Footprint — Silo Pharma, Inc.

Event summary

Silo Pharma received a Notice of Allowance from CIPO for its SPC-15 PTSD treatment patent on August 18, 2026.
The patent covers intranasal 5-HT4 receptor agonist methods for preventing stress-induced psychiatric disorders.
This follows a recently granted European patent for the same core invention.
Silo holds an exclusive license for the Canadian patent as part of its global license agreement with Columbia University.
The company plans to use the FDA’s 505(b)(2) pathway to streamline SPC-15’s clinical development.

The big picture

Silo Pharma’s Canadian patent allowance strengthens its global IP position for SPC-15, a lead asset targeting PTSD. This follows a European patent grant, signaling the company’s strategic focus on securing broad international protection for its therapeutic portfolio. The move aligns with industry trends where biopharmaceutical firms prioritize IP fortification to enhance licensing and commercialization potential. Silo’s use of the FDA’s 505(b)(2) pathway could further streamline development, reducing both time and costs.

What we're watching

Regulatory Strategy: How the FDA’s 505(b)(2) pathway will impact SPC-15’s development timeline and cost efficiency.
IP Expansion: Whether Silo can sustain its momentum in securing international patents for its lead therapeutic.
Commercialization Pace: The pace at which Silo advances SPC-15 through clinical trials following this patent milestone.